FDA warned Toyobo after inspection found unresolved particulate contamination and environmental monitoring data manipulation affecting sterile injectable drugs.
What happened
FDA inspected Toyobo's drug manufacturing facility in Otsu, Shiga, Japan, from February 15 to 19, February 22, and February 24 to 25, 2021. The agency found multiple batches of sterile injection solution with visible particulates, including extrinsic particles, and inadequate investigations into root cause and corrective actions. It also found environmental monitoring data manipulation and an insufficient investigation into the scope of data integrity breaches.
What FDA found
Failed to adequately investigate recurring visible particulate contamination, including extrinsic particles and ferrous complexes, in sterile injection solution.
21 CFR 211.192Failed to determine root cause and implement timely, effective corrective and preventive actions for persistent particulate contamination.
21 CFR 211.192Failed to adequately investigate the scope of data integrity breaches in environmental monitoring.
21 CFR 211.192Operators manipulated contact plate and nonviable particle monitoring data, making environmental monitoring unreliable and raising sterility assurance concerns.
21 CFR parts 210 and 211Had uncontrolled testing worksheets and deficient laboratory document reconciliation systems.
21 CFR parts 210 and 211Quality system did not adequately ensure accuracy and integrity of data supporting drug safety, effectiveness, and quality.
21 CFR parts 210 and 211
What FDA wants
FDA tells Toyobo to correct the violations promptly and to provide comprehensive investigations, risk assessments, CAPA plans, and consultant-led data integrity and CGMP remediation. The company must respond in writing within 15 working days.
Who should pay attention
- drugmakers relying on Toyobo for sterile injectable manufacturing
- sterile injectable manufacturers and distributors
- quality teams managing supplier and data integrity oversight
This is a summary. Read the original letter on fda.gov.